DA-1726 84th ADA Onsite Poster - DA-1726, a GLP1R/GCGR Dual Agonist, A Promising Approach in Body Composition and Lipid Management 84th ADA ePoster - DA-1726, a GLP1R/GCGR Dual Agonist, A Promising Approach in Body Composition and Lipid Management 83rd ADA Onsite Poster - A Novel GLP1R/GCGR Dual Agonist, DA-1726 Elicits Weight Loss Superior to Semaglutide in Diet-Induced Obese Rats 83rd ADA ePoster - A Novel GLP1R/GCGR Dual Agonist, DA-1726 Elicits Weight Loss Superior to Semaglutide in Diet-Induced Obese Rats 83rd ADA onsite Poster - Differentiated Metabolic Effects of DA-1726, a Balanced GLP1R/GCGR Dual Agonist 83rd ADA ePoster - Differentiated Metabolic Effects of DA-1726, a Balanced GLP1R/GCGR Dual Agonist 82nd ADA ePoster - DA-1726, a Balanced GLP1R/GCGR Dual Agonist, Effectively Controls both Body Weight and Blood Glucose 82nd ADA ePoster - Therapeutic Potential of DA-1726, a Novel Oxyntomodulin Analogue, in a Diet-Induced NASH Mouse Model DA-1241 2019 ADA – DA-1241 a novel GPR119 Agonist, Improves Hyperglycemia via Inhibition of Hepatic Glucogenesis and Enhancing Glucose Simulated Insulin Secretion via Stimulation of GLP-1 Secretion 2017 ADA – Effects of DA-1241, A Novel GPR119 Agonist, on Lipid Control in Disease Models Mediated by Regulating AMPK/SREBP1c Signaling Path 2015 ADA – Long-term Treatment of DA-1241, a Novel GPR119 Agonist, Improved Glucose Control via Preserved Beta Cell Mass in a Progressive Diabetic Mice Model Pagination First page « first Previous page ‹ previous Page 1 Current page 2
84th ADA Onsite Poster - DA-1726, a GLP1R/GCGR Dual Agonist, A Promising Approach in Body Composition and Lipid Management
84th ADA ePoster - DA-1726, a GLP1R/GCGR Dual Agonist, A Promising Approach in Body Composition and Lipid Management
83rd ADA Onsite Poster - A Novel GLP1R/GCGR Dual Agonist, DA-1726 Elicits Weight Loss Superior to Semaglutide in Diet-Induced Obese Rats
83rd ADA ePoster - A Novel GLP1R/GCGR Dual Agonist, DA-1726 Elicits Weight Loss Superior to Semaglutide in Diet-Induced Obese Rats
83rd ADA onsite Poster - Differentiated Metabolic Effects of DA-1726, a Balanced GLP1R/GCGR Dual Agonist
82nd ADA ePoster - DA-1726, a Balanced GLP1R/GCGR Dual Agonist, Effectively Controls both Body Weight and Blood Glucose
82nd ADA ePoster - Therapeutic Potential of DA-1726, a Novel Oxyntomodulin Analogue, in a Diet-Induced NASH Mouse Model
2019 ADA – DA-1241 a novel GPR119 Agonist, Improves Hyperglycemia via Inhibition of Hepatic Glucogenesis and Enhancing Glucose Simulated Insulin Secretion via Stimulation of GLP-1 Secretion
2017 ADA – Effects of DA-1241, A Novel GPR119 Agonist, on Lipid Control in Disease Models Mediated by Regulating AMPK/SREBP1c Signaling Path
2015 ADA – Long-term Treatment of DA-1241, a Novel GPR119 Agonist, Improved Glucose Control via Preserved Beta Cell Mass in a Progressive Diabetic Mice Model
